A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age

A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age

Item
http://www.wikidata.org/entity/Q35045424
Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewClinical development of Ebola vaccinesDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsProtective immunity to liver-stage malariaMalaria vaccine clinical trials: what's on the horizonA full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.Centralized Consensus Hemagglutinin Genes Induce Protective Immunity against H1, H3 and H5 Influenza Viruses.Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform.Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.Adenoviral vector-based strategies against infectious disease and cancer.Development of replication-deficient adenovirus malaria vaccines.Novel viral vectors in infectious diseases.Efficacy of an Adenoviral Vectored Multivalent Centralized Influenza Vaccine.
P2860

A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age

Item
http://www.wikidata.org/entity/Q35045424
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A phase 1b randomized, control ...... y adults 18 to 45 years of age
@en
type
label
A phase 1b randomized, control ...... y adults 18 to 45 years of age
@en
prefLabel
A phase 1b randomized, control ...... y adults 18 to 45 years of age
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
A phase 1b randomized, control ...... y adults 18 to 45 years of age
@en
P2093
P2860
P304
P31
P356
10.1371/JOURNAL.PONE.0078679
P407
P433
P478
P50
P577
P5875
P698
P921
P932